A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing

RECOMMENDED

Lung, Respiratory and Thoracic Cancer

Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France

Lung Cancer.

Chouaid C, Bensimon L, Clay E, Millier A, Levy-Bachelot L, Huang M, Levy P

doi: 10.1016/j.lungcan.

Central Nervous System TumorsLung, Respiratory and Thoracic Cancer

Significant Survival Benefit of Atezolizumab in Second-Line NSCLC Regardless of PD-L1 Status (The OAK Study)

Breast Cancer

Recent Developments in Metastatic Breast Cancer

healthbook TIMES Oncology Hematology

Lung, Respiratory and Thoracic Cancer

Cost-Effectiveness Analysis of Afatinib versus Gefitinib for First-Line Treatment of Advanced EGFR-Mutated Advanced Non-Small Cell Lung Cancers

J Thorac Oncol.

Chouaid C, Luciani L, LeLay K, Do P, Bennouna J, Perol M, Moro-Sibilot D, Vergnenègre A, de Pouvourville G

doi: 10.1016/j.jtho.2017.07.013.

Lung, Respiratory and Thoracic Cancer

Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial

Lancet Oncol.

Brahmer JR, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Zhang J, Lubiniecki GM, Deitz AC, Rangwala R Reck M

doi: 10.1016/

Lung, Respiratory and Thoracic Cancer

Cost effectiveness of pembrolizumab vs chemotherapy as first-line treatment for metastatic NSCLC that expresses high levels of PD-L1 in Switzerland

Swiss Med Wkly.

Bhadhuri A, Insinga R, Guggisberg P, Panje C, Schwenkglenks M

doi: 10.4414/smw.2019.20170.

RECOMMENDED

Lung, Respiratory and Thoracic Cancer

Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater

J Clin Oncol.

Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Vandormael K, Riccio A, Yang J, Pietanza MC, Brahmer JR

doi: 10.1200/JCO.18.00149.

Lung, Respiratory and Thoracic Cancer

A cost-effectiveness analysis of consolidation immunotherapy with durvalumab in stage III NSCLC responding to definitive radiochemotherapy in Switzerland

Ann Oncol.

Panje CM, Lupatsch JE, Barbier M, Pardo E, Lorez M, Dedes KJ, Aebersold DM, Plasswilm L, Gautschi O, Schwenkglenks M, Swiss Group for Clinical Cancer Research (SAKK).

doi: 10.1016/j.annonc.2020.01.007.

Lung, Respiratory and Thoracic Cancer

Impact of Specimen Characteristics on PD-L1 Testing in Non-Small Cell Lung Cancer: Validation of the IASLC PD-L1 Testing Guidelines

J Thorac Oncol.

Gagné A, Wang E, Bastien N, Orain M, Desmeules P, Pagé S, Trahan S, Couture C, Joubert D, Joubert P

doi: 10.1016/j.jtho.2019.08.2503.

Related content

Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France

Significant Survival Benefit of Atezolizumab in Second-Line NSCLC Regardless of PD-L1 Status (The OAK Study)

Recent Developments in Metastatic Breast Cancer

Cost-Effectiveness Analysis of Afatinib versus Gefitinib for First-Line Treatment of Advanced EGFR-Mutated Advanced Non-Small Cell Lung Cancers

Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial

Cost effectiveness of pembrolizumab vs chemotherapy as first-line treatment for metastatic NSCLC that expresses high levels of PD-L1 in Switzerland

Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater

A cost-effectiveness analysis of consolidation immunotherapy with durvalumab in stage III NSCLC responding to definitive radiochemotherapy in Switzerland

Impact of Specimen Characteristics on PD-L1 Testing in Non-Small Cell Lung Cancer: Validation of the IASLC PD-L1 Testing Guidelines